Data Published in Proceedings of National Academy of Sciences Highlights Potential of Micromet's BiTE Antibod... (against tumor cells and represent a new ...)

Data Published in Proceedings of National Academy of Sciences Highlights Potential of Micromet's BiTE Antibody Platform

Date:6/29/2010

against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, Boehringer Ingelheim, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com.

Safe Harbor

This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research

Post Your Comments:

(Date:6/18/2013)... MT. PROSPECT, Ill. , June 18, 2013 ... availability of its new X3130 Appliance Inlet Module. ... thermal circuit breaker , combines a C14 appliance ... in one compact package. This three-in-one device allows ... in their designs - cutting installation time by ...

(Date:6/18/2013)... GARDEN CITY, N.Y. , June 18, 2013 ... announced that it has entered into an exclusive ... and Mid-Atlantic regions with eWellness Corporation ("EWC") for ... "An easy to use physical therapy program ... of diabetes and cardiovascular disease," said Chris ...

(Date:6/18/2013)... a letter to authorities at her hospital, orthopaedic surgeon ... Iowa , writes that a policy of forcing all ... justified nor ethically sound. Her letter is the ... the Journal of American Physicians and Surgeons. ... of 36,000 patients per year die in U.S. hospitals from ...

Breaking Medicine Technology:Three-in-One X3130 Appliance Inlet Module 2 Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 2 Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 3 Mandated Flu Vaccine for Hospital Workers Ethically Questionable, Surgeon Writes 2

[0] Three-in-One X3130 Appliance Inlet Module [0] Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions [0] Mandated Flu Vaccine for Hospital Workers Ethically Questionable, Surgeon Writes

... Ga., Dec. 23, 2010 MiMedx Group, ... integrated developer, manufacturer and marketer of patent protected biomaterial-based ... the Class III certification for a European product using ... certification for "post surgical adhesion inhibiting barriers" is in ...

... Pa., Dec. 23, 2010 Cephalon, Inc. (Nasdaq: ... appointed J. Kevin Buchi as Chief Executive Officer and a ... role of company Chairman in the future. William P. Egan ... "Kevin is an experienced pharmaceutical executive who has been ...

Cached Medicine Technology:MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 2 MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 3 MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 4 Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors 2 Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors 3 Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors 4

MiMedx Receives Additional CE Certification for Its HydroFix™ Technology Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors

(Date:6/19/2013)... Francisco, CA (PRWEB) June 19, 2013 ... accelerating throughout 2013 across all industries as cash rich ... Despite the differences across industries, all M&A transactions have ... rigorous due diligence to verify the history and quality ... carefully considered. , But when due diligence involves ...

(Date:6/18/2013)... 19, 2013 Consumer injury attorney Michael ... law firms have launched a new website for people ... dialysis. The website is http://www.DialysisLawsuitAttorneys.com . , "My ... begin offering legal services to people who may have ... NaturaLyte, or who may have suffered injuries due to ...

(Date:6/18/2013)... Exposed Skin Care has finally been released ... of all ages finally achieve the clear, beautiful skin they ... new acne clearing system combines the power of science and ... from forming. , After a quick review ... some of the most effective available on the market to ...

(Date:6/18/2013)... 2013 Parker Waichman LLP, a national ... injured by dangerous drugs and medical devices, has filed ... alleges that she was injured by transvaginal mesh ... in the U.S. District Court for the Southern District ... multidistrict litigation entitled In Re: American Medical Systems, Inc., ...

(Date:6/18/2013)... York, NY (PRWEB) June 18, 2013 Cheap ... tickets for the tournament which gets underway in July. ... savings on any CONCACAF ticket order. , The ... and cranny of the globe. In fact, the hype of the ... Its popularity also trickled down the veins of fans ...

Breaking Medicine News(10 mins):Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 2 Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 3 Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 2 Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 3 Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 4 Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2 Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3 Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 2 Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 3 Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 4 Health News:CONCACAF Tickets Have Been Released for Martinique, Mexico, Panama, El Salvador, Trinidad, Tobago, Haiti, Honduras, Costa Rica, Cuba, Belize, US, Canada, Honduras & Cuba 2 Health News:CONCACAF Tickets Have Been Released for Martinique, Mexico, Panama, El Salvador, Trinidad, Tobago, Haiti, Honduras, Costa Rica, Cuba, Belize, US, Canada, Honduras & Cuba 3

[0] Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company [0] Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama [0] Exposed Skin Care Review Released by ExposedSkinCareReview.org [0] Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman [0] CONCACAF Tickets Have Been Released for Martinique, Mexico, Panama, El Salvador, Trinidad, Tobago, Haiti, Honduras, Costa Rica, Cuba, Belize, US, Canada, Honduras & Cuba

... AUSTIN, Texas Employees who have more control over their ... to be in better health, according to a new study ... month,s Journal of Health and Social Behavior. , "The most ... said lead author John Mirowsky, a sociology professor with the ...

... 18, 2007 -- Phylonix Pharmaceuticals today announced that it ... 135 531 B1: Methods for Introducing Heterologous Cells into ... European countries, encompasses 68 claims, including transplanting stem cells, ... chondrocytes, renal and hepatic cells can be transplanted in ...

... CBS News will be running the,story December 17th and ... CHEMOTHERAPY, THANKS TO A NEW ROBOT THAT MEASURES AND ... PharmD, PhD, and,a patient were interviewed by CBS News. ... compounding for syringes and IV bags.,University of Colorado Hospital ...

... AIDS Healthcare,Foundation (AHF) today strongly criticized Ryan White ... package drafted by Congress in order,to meet the ... for,next year. The fiscal year 2008 Labor-Health and ... today and is,expected to be introduced in the ...

... Toronto Stock Exchange Symbol: CYT, MONTREAL, Dec. 17 ... products to treat cardiovascular,disease, today announced financial results for ... Selected FY 2007 Financial and Operating Highlights:, ... portfolio to ATS Medical, we ...

... ... -, TOPEKA, Kan., Dec. ... Kansas, which will,help support the needs of more than 7,700 Kansas Guard members ... at,TriWest, will present the check to the Adjutant General of the Kansas,National Guard, ...

Creative work has health advantages, Population Research Center study shows Phylonix granted broad European patent for transplanting human cells into zebrafish CytoCare Showcased on CBS News Nationally and CBS Affiliates Ryan White Funding Proposal Demonstrates Neglect of US' Growing AIDS Epidemic, Says AHF CryoCath announces 2007 fourth quarter and fiscal year end financial results TriWest Contributes $15,000 to Kansas National Guard Fund

Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....

Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....

Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....

... 4F, 5F, and 6F ... is ideal for coronary ... state-of-the-art technology and proprietary ... better responsiveness, optimal torque, ...

Medicine Products:

7F High Flow 6F Infiniti 5F Infiniti Infinity